Kailera Therapeutics (KLRA) News
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.02-0.56 (-4.84%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KLRA news summary
We found 5 recent headlines mentioning Kailera Therapeutics (KLRA): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, KLRA is down 4.84% at $11.02. The most recent story, "Canaccord Genuity Initiates Coverage of Kailera Therapeutics with Buy Rating", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Kailera Therapeutics headlines
- Canaccord Genuity Initiates Coverage of Kailera Therapeutics with Buy RatingFintel reports that on November 9, 2026, Canaccord Genuity initiated coverage of Kailera Therapeutics (NASDAQGS:KLRA) with a Buy recommendation.NasdaqKLRA, BIO.B
- Kailera Therapeutics reports Q3 resultsSeeking Alpha
- Kailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesKailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Kailera Therapeutics to Participate in November Investor ConferencesRon Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferencesGlobeNewswire
- 3 Under-the-Radar Stocks to Buy and Hold for a DecadeKey PointsThese three innovative biotechs are developing products in markets with high unmet needs.NasdaqMDGL, LLY, NVO, AXSM